Evidence for a differential cholecystokinin-B and -A receptor regulation of GABA release in the rat nucleus accumbens mediated via dopaminergic and cholinergic mechanisms

Neuroscience

Volumn 73, Issue 4, 1996, Pages 941-950

  Ferraro, L ^a   O'Connor, W T ^b   Li, X M ^a   Rimondini, R ^a   Beani, L ^c   Ungerstedt, U ^a   Fuxe, K ^a   Tanganelli, S ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

anaesthetized rat; cholecystokinin; microdialysis; receptor binding; receptor receptor interaction

Indexed keywords

4 AMINOBUTYRIC ACID; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ACETYLCHOLINE; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ OCTAPEPTIDE; DEVAZEPIDE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; MUSCARINIC M2 RECEPTOR ANTAGONIST; OTENZEPAD; PROPYLNORAPOMORPHINE;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; CORPUS STRIATUM; DISSOCIATION CONSTANT; DOPAMINERGIC TRANSMISSION; DRUG BINDING SITE; FACILITATION; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

EID: 0029994752     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(96)00098-X     Document Type: Article

References (57)

1. 3H]N-propylnorapomorphine sites. Acta physiol. scand. 118, 79-81.
2. Agnati L. F., Fuxe K., Zoli M., Benfenati F. and Goldstein M. (1985) Evidence for CCK-DA receptor interactions in the CNS of the adult and old rat. Ann. N. Y. Acad. Sci. 448, 315-333.
3. 2 receptors in the nucleus accumbens of the rat. Brain Res. 501, 389-391.
4. 2 receptors in rat nucleus accumbens: resistance to differential rearing conditions. Neuroscience 45, 281-290.
5. Barnes S., Whistler H. L., Hughes, J., Woodruff G. N. and Hunter J. C. (1991) Effect of cholecystokinin octapeptide on endogenous amino acid release from the rat ventromedial nucleus of the hypothalamus and striatum. J. Neurochem. 56, 1409-1416.
6. Chang H. T. and Kitai S. T. (1985) Projection neurones in the nucleus accumbens: an intracellular labelling study. Brain Res. 347, 112-116.
7. Chang R. S. L. and Lotti V. J. (1986) Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc. natn. Acad. Sci. U.S.A. 83, 4923-4926.
8. Crawley J. N. (1991) Cholecystokinin-dopamine interactions. Trends pharmac. Sci. 12, 232-236.
9. 2 dopaminergic receptors in the emotional and motivational responses induced by injection of CCK-8 in the posterior part of the rat nucleus accumbens. Brain Res. 617, 181-188.
10. 2) mediated inhibition of the electrically-evoked endogenous GABA release from guinea pig cerebral cortex slices. Polish J. Pharmac. 46, 308-309.
11. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 63, 765-773.
12. Freeman A. S. and Chiodo L. A. (1987) Cholecystokinin/dopamine interactions in the central nervous system. In Neurophysiology of Dopaminergic Systems. Current Status and Clinical Perspectives (eds Chiodo L. A. and Freeman A. S.), pp. 205-236. Lakeshore, Gross Point, MI.
13. Fuxe K. and Ungerstedt U. (1970) Histochemical, biochemical and functional studies on central monoamine neurons after acute and chronic amphetamine administration. In Amphetamines and Related Compounds (eds Costa E. and Garattini S.), pp. 57-288. Proc. Mario Negri Inst. Pharmac. Res., Milan.
14. 2 transmission lines in the central nervous system. In Current Aspects in the Neurosciences (ed. Osborne H.), Vol. 1, pp. 203-243. MacMillan Press, Basingstoke.
15. Fuxe K., Li X. M., Tanganelli S., Hedlund P., O'Connor W. T., Ferraro L., Ungerstedt U. and Agnati L. F. (1994) Receptor-receptor interactions and their relevance for receptor diversity: focus on neuropeptide/dopamine interactions. Conference on Functional Diversity of Interacting Receptors. Ann. N.Y. Acad. Sci. 757, 365-376.
16. Groenewegen H. J., Berendse H. W., Meredith G. E., Haber S. N., Voorn P., Wolters J. G. and Lohman A. H. M. (1991) Functional anatomy of the ventral, limbic system-innervated striatum. In The Mesolimbic Dopamine System (eds Willner P. and Scheel-Kruger J.), pp. 19-59. Wiley, New York.
17. 1A receptors increases the affinity of galanin receptors in di- and telencephalic areas of the rat. Brain Res. 560, 251-259.
18. Heimer L., Alheid G. F. and Zahm D. S. (1993) Basal forebrain organization: an anatomical framework for motor aspects of drive and motivation. In Limbic Motor Circuits and Neuropsichiatry (eds Kalivas P. W. and Barnes C. D.), pp. 1-43. CRC Press, Boca Raton, FL.
19. Hökfelt T., Skiboll L., Rehfeld M. F., Goldstein M., Markey K. and Dann O. (1980) A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contain a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 5, 2093-2124.
20. Hökfelt T., Rehfeld J. F., Skirboll L., Ivemark B., Goldstein M. and Markey K. (1980) Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature 285, 476-478.
21. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D. C., Hunter J. C., Pinnock R. D. and Woodruff G. N. (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. natn. Acad. Sci. U.S.A. 87, 6728-6732.
22. Kehr J. and Ungerstedt U. (1988) Fast HPLC estimation of gamma-aminobutyric acid in microdialysis perfusate: effect of nipecotic acid and 3-mercaptopropionic acid. J. Neurochem. 51, 1308-1310.
23. B-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res. 628, 254-262.
24. Larsson L. I. and Rehfeld J. F. (1979) Localization and molecular heterogeneity of cholecystokinin in the central nervous system. Brain Res. 165, 201-218.
25. 2 receptors induced by cholecystokinin receptor subtypes in rat neostriatal membranes. Brain Res. 650, 289-298.
26. 2 receptors in sections of rat basal ganglia. Eur. J. Neurosci. 7, 962-971.
27. Marchi M., Sanguineti P. and Raiteri M. (1990) Muscarinic receptors mediate direct inhibition of GABA release from rat striatal nerve terminals. Neurosci. Lett. 116, 347-351.
28. Marshall F. H., Barnes S., Hughes J., Woodruff G. N. and Hunter J. C. (1991) Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J. Neurochem. 56, 917-922.
29. Meredith G. E., Blank B. and Groenewegen H. J. (1989) The distribution and compartmental organization of the cholinergic neurons in nucleus accumbens of the rat. Neuroscience 31, 327-345.
30. Moore R. J. and Bloom F. E. (1978) Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. A. Rev. Neurosci. 1, 129-169.
31. Moran T. H., Robinson P. H., Goldrich M. S. and McHugh P. R. (1986) Two brain cholecystokinin receptors: implications for behavioural actions. Brain Res. 361, 175-179.
32. Morari M., O'Connor W. T., Ungerstedt U. and Fuxe K. (1993) N-Methyl-D-aspartic acid differentially regulates extracellular dopamine, GABA and glutamate levels in the dorsolateral neostriatum of the halothane anaesthetized rat: an in vivo microdialysis study. J. Neurochem. 60, 1884-1893.
33. Motulsky H. J. and Ransnas L. A. (1987) Fitting curves to data using nonlinear regression: a practical and nonmathematical review. Fedn Proc. Fedn Am. Socs exp. Biol. 1, 365-374.
34. 3H]dopamine binding by cholecystokinin octapeptide. Peptides 3, 539-543.
35. O'Connor W. T., Tanganelli S., Ungerstedt U. and Fuxe K. (1992) The effects of neurotensin on GABA and acetylcholine release in the dorsal striatum of the rat: an in vivo microdialysis study. Brain Res. 573, 209-216.
36. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
37. 3H]-gamma-aminobutyric acid release in slices from various brain areas. Eur. J. Pharmac. 250, 423-430.
38. Phillips G. D., Le Noury J., Wolterink G., Donselaar-Wolterink I., Robbins T. W. and Everitt B. J. (1993) Cholecystokinin-dopamine interactions within the nucleus accumbens in the control over behaviour by conditioned reinforcement. Behav. Brain Res. 55, 223-231.
39. Rada P. V., Mark G. P. and Hoebel B. G. (1993) In vivo modulation of acetylcholine in the nucleus accumbens of freely moving rats: II. Inhibition by γ-aminobutyric acid. Brain Res. 619, 105-110.
40. Raiteri M., Marchi M., Paudice P. and Pittaluga A. (1990) Muscarinic receptors mediating inhibition of gamma-aminobutyric acid release in rat corpus striatum and their pharmacological characterization. J. Pharmac. exp. Ther. 254, 496-501.
41. B antagonist LY 262691 decreases midbrain dopamine unit activity. Eur. J. Pharmac. 209, 135-138.
42. Rehfeld J. F. (1985) Neuronal cholecystokinin: one or multiple transmitters. J. Neurochem. 44, 1-9.
43. Ruggeri M., Ungerstedt U., Agnati L. F., Mutt V., Harfstand A. and Fuxe K. (1987) Effects of cholecystokinin peptides and neurotensin on dopamine release and metabolism in the rostral and caudal parts of the nucleus accumbens using intracerebral microdialysis in the anaesthetized rat. Neurochem. Int. 10, 509-520.
44. Schalling M., Friberg K., Seroogy K., Riederer P., Bird E., Schffman S. N., Mallieux P., Vanderhaeghen J. J., Kuga S. and Goldstein M. (1990) Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and humans with schizophrenia. Proc. natn. Acad. Sci. U.S.A. 87, 8427-8431.
45. Smith S. E. and Scharp T. (1994) An investigation of the origin of extracellular GABA in rat nucleus accumbens measured in vivo by microdialysis,. J. neural Transm. (Gen. Sect.) 97, 161-171.
46. Snedecor G. W. and Cochran W. C. (1980) Statistical Methods, pp. 291-292. Iowa State University, Ames, IA.
47. Tanganelli S., Fuxe K., von Euler G., Agnati L. F., Ferraro L. and Ungerstedt U. (1990) Involvement of cholecystokinin receptors in the control of striatal dopamine autoreceptors. Naunyn-Schmiedeberg's Arch. Pharmac. 342, 300-304.
48. Tanganelli S., O'Connor W. T., Ferraro L., Bianchi C., Beani L., Ungerstedt U. and Fuxe K. (1994) Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neuroscience 60, 649-657.
49. Vanderhaeghen J. J., Signeau J. C. and Gept W. (1975) New peptide in the vertebrate CNS reacting with gastrin antibodies. Nature 257, 604-605.
50. Van Ree J. M., Gaffori O. and De Wied D. (1983) In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents. Eur. J. Pharmac. 93, 63-78.
51. 3H]dopamine efflux from rat nucleus accumbens. Neuropeptides 13, 43-50.
52. Voight M. M., Wang R. Y. and Westfall T. C. (1986) Cholecystokinin-octapeptides alter the release of endogenous dopamine from rat nucleus accumbens in vitro. J. Pharmac. exp. Ther. 237, 147-153.
53. Wang R. Y. (1988) Cholecystokinin, dopamine and schizophrenia: recent progress and current problems. In The Mesocorticolimbic System (eds Kalivas P. W. and Nemeroff G. B.). Ann. N. Y. Acad. Sci. 537, 362-379.
54. Weiss F., Tanzer D. J. and Ettenberg A. (1988) Opposite actions of CCK-8 on amphetamine-induced locomotion and stereotypy following intracerebroventricular and intraaccumbens injections in rats. Pharmac. Biochem. Behav. 30, 309-312.
55. Wiesenfeld-Hallin Z., Xu X. J., Hughes J., Horwell D. C. and Hökfelt T. (1990) PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc. natn. Acad. Sci. U.S.A. 87, 7105-7109.
56. Winer B. J. (1971) Statistical Principles in Experimental Design. McGraw-Hill, New York.
57. Zetler G. (1985) Neuropharmacological profile of cholecystokinin-like peptides. Ann. N. Y. Acad. Sci. 448, 448-469.